Evidence map›Paper›PMID 33965621›Full record

Observational studyTransfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine2021

Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions.

S Mahapatra, R Rattan, C B K Mohanty

Open access · greenAbstract readComparative StudyMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

S MahapatraC/O-Mr NK Mishra, N-1/256, Nayapalli, IRC Village, Bhubaneswar, Odisha, 751015, India; Department of Transfusion Medicine, S.C.B. Medical College & Hospital, Cuttack, Odisha, 753007, India. Electronic address: doctorsmita@rediffmail.com.
R RattanPlot no-C-1208, Sector 6, CDA, Bidanasi, Cuttack, Odisha 753014, India; Department of Biochemistry, SCB Medical College & Hospital, Cuttack, Odisha, India.
C B K MohantyNetaji Nagar, Cuttack, Odisha 753010, India; Medical Education & Training, Bhubaneswar, Odisha, India.
Sriram Chandra Bhanja Medical College Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID 19 infection caused by novel coronavirus with no specific established treatment. Convalescent Plasma Therapy has been authorized as an off-label therapeutic procedure. We assessed the outcome of convalescent plasma (CP) units versus standard treatment on the complete recovery, improvement and 28 days' mortality of COVID 19 patients. MATERIALS AND

methodsThe present was multi-centric case controlled observational prospective study. The study was conducted for a period of four and half months from July 15 2020 to 30 November 2020 after taking approval from the Expert Committee, Health & Family Welfare Department, Government of Odisha. Plasma therapy was applied on two groups of 1189 serious COVID patients (959 number of pre- critical and 230 number of critical patients) not responding to oxygen therapy. It was compared with non- transfused control group of 1243 patients (996 number of pre-critical and 247 number of critical patients).

resultsDischarge was better in (55.5%) transfused than (43%)in non-transfused pre-critical patients and the mortality was lower (44.3%) in transfused, (48.9%) than non-transfused critical patients respectively. Complete recovery was highest in those who were transfused with CP with neutralizing titer more than 1:160 (52.5%), 18-30 years' age group (64%), females (53%), 'O' Rh D positive blood group (51.5%). There was no adverse reaction due to CP transfusion.

conclusionsCP is effective in improving the recovery rate with earlier discharge and decrease in the 28 days' mortality than in the control non-transfused group. CP with neutralizing antibody titer more than 1:160 has the best outcome with complete recovery and decrease in the mortality. It is more effective in treating pre-critical patients when transfused early, in female patients, in younger age group and in blood group 'O' Rh D positive.

Indexed as

SARS-CoV-2AdolescentAdultAge DistributionAntibodies, NeutralizingAntibodies, ViralBlood Group AntigensCase-Control StudiesCOVID-19COVID-19 SerotherapyDisease ManagementDonor SelectionFemaleHumansImmunization, PassiveIndiaAntibodies, NeutralizingAntibodies, ViralBlood Group AntigensConvalescent plasmaCOVID 19 infectionEarly transfusionMortality

Identifiers

PMID33965621
PMCPMC8132190
OpenAlexW3157358986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.